Literature DB >> 20155450

Isolation of cultured endothelial progenitor cells in vitro from PBMCs and CD133(+) enriched cells.

Weihong Zheng1, Yafeng Wan, Xiaopeng Ma, Xingrui Li, Zhifang Yang, Qian Yin, Jilin Yi.   

Abstract

Two isolation methods for sorting of endothelial progenitor cells (EPCs): from peripheral blood mononuclear cells (PBMCs) and CD133(+) enriched cells were compared, by defining the cell morphology, phenotype, reproductive activities and function in vitro, to provide a reference for clinical application of EPCs. PBMCs from healthy subjects were used either directly for cell culture or for CD133(+) sorting. The two groups of cells were cultured in complete medium 199 (M199) for 7 to 14 days and the phenotypes of EPCs were analyzed by FACS. The proliferation of differentiated EPCs was studied by MTT assay, and the VEGF concentration was measured using an ELISA kit. ECM gel experiment and migration assay were performed in vivo. The results showed that PBMCs produced more colony-forming units (CFU) than CD133(+) enriched cells from the same volume of blood (P<0.01). From day 7 to 14, the two groups showed decreased expression of hematopoietic stem cell markers and increased level of endothelial markers, but CD144(+) cells in CD133(+) group were less than in PBMCs group (P<0.01). PBMCs group secreted more VEGF than CD133(+) group on the day 7 (P<0.01). As compared with CD133(+) group, PBMCs group had more potent potential of proliferation and vascularization in vitro. It was concluded that CD133(+) sorted cells showed a lower capacity of differentiation, secretion, proliferation and vascularization in vitro, suggesting that CD133-negative cells may be a preferential way to get EPCs for clinical therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20155450     DOI: 10.1007/s11596-010-0104-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  26 in total

1.  Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.

Authors:  Mervin C Yoder; Laura E Mead; Daniel Prater; Theresa R Krier; Karim N Mroueh; Fang Li; Rachel Krasich; Constance J Temm; Josef T Prchal; David A Ingram
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

2.  Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7.

Authors:  L Gallacher; B Murdoch; D M Wu; F N Karanu; M Keeney; M Bhatia
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

3.  In vitro differentiation of endothelial cells from AC133-positive progenitor cells.

Authors:  U M Gehling; S Ergün; U Schumacher; C Wagener; K Pantel; M Otte; G Schuch; P Schafhausen; T Mende; N Kilic; K Kluge; B Schäfer; D K Hossfeld; W Fiedler
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

4.  Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells.

Authors:  Carmen Urbich; Alexandra Aicher; Christopher Heeschen; Elisabeth Dernbach; Wolf K Hofmann; Andreas M Zeiher; Stefanie Dimmeler
Journal:  J Mol Cell Cardiol       Date:  2005-09-29       Impact factor: 5.000

5.  Peripheral endothelial progenitor cells (CD133 +) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up.

Authors:  M C Cañizo; F Lozano; J R González-Porras; M Barros; N López-Holgado; E Briz; F M Sánchez-Guijo
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

6.  Isolation of putative progenitor endothelial cells for angiogenesis.

Authors:  T Asahara; T Murohara; A Sullivan; M Silver; R van der Zee; T Li; B Witzenbichler; G Schatteman; J M Isner
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

7.  Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells.

Authors:  Menachem Bitan; Michael Y Shapira; Igor B Resnick; Irina Zilberman; Svetlana Miron; Simcha Samuel; Aliza Ackerstein; Sharon Elad; Shosh Israel; Avraham Amar; Eitan Fibach; Reuven Or; Shimon Slavin
Journal:  Exp Hematol       Date:  2005-06       Impact factor: 3.084

Review 8.  Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy.

Authors:  Balazs Dome; Jozsef Timar; Andrea Ladanyi; Sandor Paku; Ferenc Renyi-Vamos; Walter Klepetko; Gyorgy Lang; Peter Dome; Krisztina Bogos; Jozsef Tovari
Journal:  Crit Rev Oncol Hematol       Date:  2008-09-03       Impact factor: 6.312

9.  A comparison of CFU-GM, BFU-E and endothelial progenitor cells using ex vivo expansion of selected cord blood CD133(+) and CD34(+) cells.

Authors:  X Lu; S V Baudouin; J I Gillespie; J J Anderson; A M Dickinson
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

10.  Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies.

Authors:  Jin Hur; Han-Mo Yang; Chang-Hwan Yoon; Choon-Soo Lee; Kyung-Woo Park; Ji-Hyun Kim; Tae-Youn Kim; Ju-Young Kim; Hyun-Jae Kang; In-Ho Chae; Byung-Hee Oh; Young-Bae Park; Hyo-Soo Kim
Journal:  Circulation       Date:  2007-10-01       Impact factor: 29.690

View more
  2 in total

1.  Proliferation characteristics of CD133+ cell population in colorectal cancer.

Authors:  Dongdong Yu; Yonghong Zhang; You Zou; Jichao Qin; Xiaolan Li; Hui Xiao; Deding Tao; Junbo Hu; Jianping Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

2.  The cross-talk between ROS and p38MAPKα in the Ex Vivo expanded human umbilical cord blood CD133(+) cells.

Authors:  Jing Zou; Ping Zou; Yi Lou; Yin Xiao; Jie Wang; Lingbo Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.